Lisanti Capital Growth LLC Takes Position in Adaptive Biotechnologies Corporation $ADPT

Lisanti Capital Growth LLC purchased a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 299,180 shares of the company’s stock, valued at approximately $4,476,000.

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC lifted its holdings in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after acquiring an additional 2,914 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at approximately $93,000. KLP Kapitalforvaltning AS lifted its stake in shares of Adaptive Biotechnologies by 42.9% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 25,000 shares of the company’s stock valued at $291,000 after purchasing an additional 7,500 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Adaptive Biotechnologies by 9.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 32,038 shares of the company’s stock valued at $373,000 after purchasing an additional 2,880 shares in the last quarter. 99.17% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ADPT. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday. Guggenheim upped their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.22.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT opened at $18.50 on Friday. Adaptive Biotechnologies Corporation has a 52-week low of $6.26 and a 52-week high of $20.76. The company has a market cap of $2.82 billion, a PE ratio of -34.26 and a beta of 2.18. The firm’s 50 day moving average price is $17.29 and its 200-day moving average price is $14.97.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The business had revenue of $93.97 million for the quarter, compared to analysts’ expectations of $58.76 million. During the same period in the prior year, the firm posted ($0.22) EPS. The firm’s quarterly revenue was up 102.4% on a year-over-year basis. On average, analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 27,212 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $18.61, for a total transaction of $506,415.32. Following the transaction, the insider owned 1,242,312 shares in the company, valued at approximately $23,119,426.32. This represents a 2.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Francis Lo sold 113,890 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30. Following the sale, the insider directly owned 315,978 shares in the company, valued at approximately $4,919,777.46. The trade was a 26.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,442,530 shares of company stock worth $24,610,748 in the last quarter. Insiders own 6.40% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.